pexels-photo-29110700_1775036885724_1775036893019_1780397242729_ad6f5473-79cd-49ef-93b2-d3ed5a373810.jpeg

After a dull Q4, Glenmark Pharma needs a booster shot to grow

Focus on execution

Meanwhile, investors’ focus is now shifting from licensing income to execution. Glenmark’s management has guided for FY27 revenue at 17,000-18,000 crore. FY26 reported revenue was 16,983 crore and core revenue was 13,000 crore. Management expects FY27 Ebitda margin at 21-22%.


Source link

Tags: No tags

Leave A Comment

Your email address will not be published. Required fields are marked *